Market Newsdesk

April 21, 2026 12:12 pm

Defiance’s Quantum Computing ETF (QTUM) Surpasses $4 Billion in Assets and Earns 5-Star Morningstar Rating

MIAMI, April 21, 2026 (GLOBE NEWSWIRE) — Defiance ETFs today announced that its Quantum Computing ETF (QTUM) has surpassed $4 billion in assets under management and has earned a 5-star Morningstar® Rating, reflecting strong risk-adjusted performance within its peer group.

The Morningstar Rating™ is based on risk-adjusted returns for the three- and five-year periods, with QTUM rated among 221 funds (three-year) and 199 funds (five-year) in the US Fund Technology category as of March 31, 2026.

Launched in September 2018, QTUM is among the earliest ETFs to provide targeted, rules-based exposure to companies advancing quantum computing, machine learning, and related enabling technologies. The fund seeks to track the performance of companies involved in the development of next-generation computing infrastructure, including quantum hardware, software, semiconductors, and supporting technologies.

Since inception (September 2018), QTUM has delivered a 354.76% cumulative total return through March 31, 2026. Over the one-year period ending March 31, 2026, the fund returned 44.88% at NAV, net of fees.*

*All figures represent total return at NAV, net of fees.

Standardized Performance as of 03/31/2026

	YTD	1 Month	3 Months	6 Months	1 Year	3 Years	5 Years	Since Inception
Total Return NAV (%)	-2.54%	-8.50%	-2.54%	2.28%	44.88%	33.18%	19.01%	22.15%
Market Price (%)	-1.95%	-7.64%	-1.95%	2.90%	45.60%	33.37%	19.10%	22.26%

For more details visit www.defianceetfs.com/qtum/#standardized-performance

QTUM provides focused exposure to companies advancing quantum computing, machine learning, and artificial intelligence, including leaders in quantum hardware, software, semiconductors, and enabling technologies. As quantum computing continues to evolve from academic research into commercial, industrial, and national-security applications, investor demand for scalable, future-oriented exposure has accelerated. These technologies are increasingly viewed as foundational to the next era of AI-driven innovation.

“Investors are increasingly rethinking what constitutes core technology exposure,” said Sylvia Jablonski, Chief Investment Officer of Defiance ETFs. “Traditional tech benchmarks are heavily weighted toward software and SaaS models that could be disrupted by advances in artificial intelligence and quantum computing. QTUM is designed as a new core technology allocation—focused on the companies building the foundational computing infrastructure of the future, with diversified exposure across quantum, AI, and enabling technologies.”

QTUM has become a core allocation for investors seeking exposure to transformative computing technologies, benefiting from increased adoption across artificial intelligence, advanced semiconductors, cloud infrastructure, and defense-related applications. Asset growth has been driven by sustained net inflows, expanding institutional participation, and QTUM’s established leadership in the category.

About Defiance ETFs

Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs. Our first-mover leveraged single-stock ETFs empower investors to take amplified positions in high-growth companies, providing precise leverage exposure without the need to open a margin account.

Past performance does not guarantee future results. Fund holdings and sector allocations are subject to change at any time and should not be considered recommendations to buy or sell any security.

The Funds’ investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contains this and other important information about the investment company. Please read it carefully before investing. A hard copy of the prospectus can be requested by calling 833.333.9383.

Morningstar Disclaimer: The Morningstar Rating™ for funds, or “star rating”, is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product’s monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Past performance is no guarantee of future results. ©2025 Morningstar, Inc. All Rights Reserved. Investing involves risk. Principal loss is possible. The Funds are not actively managed and would not sell a security due to current or projected under performance unless that security is removed from the Index or is required upon a reconstitution of the Index. A portfolio concentrated in a single industry or country may be subject to a higher degree of risk. The value of stocks of information technology companies are particularly vulnerable to rapid changes in technology product cycles, rapid product obsolescence, government regulation and competition.

The Fund is considered to be non-diversified, so it may invest more of its assets in the securities of a single issuer or a smaller number of issuers. Investments in foreign securities involve certain risks including risk of loss due to foreign currency fluctuations or to political or economic instability. This risk is magnified in emerging markets. Small and mid-cap companies are subject to greater and more unpredictable price changes than securities of large-cap companies.

The possible applications of quantum computing are only in the exploration stages, and the possibility of returns is uncertain and may not be realized in the near future. The “BlueStar Quantum Computing and Machine Learning Index™”, “BQTUM™ Index” (collectively “Quantum Computing and Machine Learning Index”), is the exclusive property and a trademark of BlueStar Global Investors LLC d/b/a BlueStar Indexes® and has been licensed for use for certain purposes by Defiance ETFs LLC. Products based on the Quantum Computing and Machine Learning Index are not sponsored, endorsed, sold or promoted by BlueStar Global Investors, LLC or BlueStar Indexes®, and BlueStar Global Investors, LLC and BlueStar Indexes® makes no representation regarding the advisability of trading in such product(s). It is not possible to invest directly in an index.

QTUM is distributed by Foreside Fund Services, LLC.

Media Contact:

Sylvia Jablonski
[email protected]
833.333.9383

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ae63ef7e-767d-45d0-ae02-d29d174d645b

April 21, 2026 12:03 pm

Piper Sandler Companies to Announce First Quarter 2026 Financial Results and Host a Conference Call on May 1, 2026

Piper Sandler Companies to Announce First Quarter 2026 Financial Results and Host a Conference Call on May 1, 2026

MINNEAPOLIS–(BUSINESS WIRE)–Piper Sandler Companies (NYSE: PIPR), a leading investment bank, will release its first quarter 2026 financial results prior to the opening of the market on Friday, May 1, 2026. The earnings release will be available at the company’s website at pipersandler.com/earnings.

Chad Abraham, chairman and chief executive officer; Deb Schoneman, president; and Kate Clune, chief financial officer, will host a related conference call at 8:30 a.m. ET (7:30 a.m. CT) that same day to review the financial results. There will be a question and answer session following the review.

Investors and analysts may participate in the live conference call by dialing 800 330-6710 (in the U.S.) or +1 312 471-1353 (outside the U.S.) and passcode 5642050. Please dial in at least 15 minutes prior to the call time.

A live audio webcast of the conference call will be available through the company’s website at pipersandler.com/earnings. A replay of the conference call will be available after the event through the same link.

Please direct any questions regarding obtaining access to the conference call to Piper Sandler Investor Relations, via email, at [email protected].

ABOUT PIPER SANDLER

Piper Sandler Companies (NYSE: PIPR) is a leading investment bank driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the U.S. through Piper Sandler & Co., member SIPC and NYSE; in the U.K. through Piper Sandler Ltd., authorized and regulated by the U.K. Financial Conduct Authority; in the EU through Aviditi Capital Advisors Europe GmbH, a tied agent of AHP Capital Management GmbH, authorized and regulated by BaFin; and in the Abu Dhabi Global Market through Piper Sandler MENA Ltd., authorized and regulated by the ADGM Financial Services Regulatory Authority. Alternative asset management and fixed income advisory services are offered through separately registered advisory affiliates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421309773/en/

Kate Clune

Tel: 212 466-7799

[email protected]

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Finance Banking Accounting Professional Services Asset Management

MEDIA:

Logo

April 21, 2026 12:03 pm

UPS and Happy Returns Cement Position as Largest Box-Free, Label-Free Return Network with Expansion to 10,000 U.S. Locations

UPS and Happy Returns Cement Position as Largest Box-Free, Label-Free Return Network with Expansion to 10,000 U.S. Locations

Partnerships with Annex Brands and PackageHub Business Centers® add 1,700 new Return Bar® locations, giving consumers more access to hassle-free returns for an immediate refund

ATLANTA–(BUSINESS WIRE)–
UPS (NYSE: UPS) and Happy Returns today announced a significant expansion of the Return Bar® network, reaching a new milestone of 10,000 drop-off locations nationwide. This growth adds more than 1,700 locations, primarily through new partnerships with Annex Brands and PackageHub Business Centers®, and removes friction across the e‑commerce experience for retailers and consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421965642/en/

Building on a strong foundation of trusted partners including The UPS Store®, Staples and Ulta Beauty, this expansion through UPS Authorized Shipping Outlets (ASOs) reinforces Happy Returns’ position as the largest consolidated return network in the U.S., now more than three times the size of the next-largest alternative. As businesses of all sizes tackle increasing returns volume, UPS and Happy Returns operate the only end-to-end reverse logistics network that supports the full lifecycle of e-commerce orders – from delivery through return or exchange.

“We are putting our customers – and their consumers – at the center of our reverse logistics business,” said Matt Guffey, Executive Vice President, Chief Commercial and Strategy Officer at UPS. “We are simplifying the end-to-end e-commerce journey, and when it comes to returns or exchanges, UPS and Happy Returns have a network that is unmatched.”

Making returns easy and convenient

Shoppers can find Return Bar® locations in stores they visit for everyday shipping and errands, making returns a simple part of their regular routine.

With the addition of the new locations, 79% of the U.S. population now lives within five miles of a Return Bar®, up from 76% previously. Additionally, more than a quarter of Americans now live within one mile of a convenient drop-off location.

“Our goal is to make returns seamless,” said David Sobie, co-founder and CEO of Happy Returns. “Our Return Bar® network is now more than three times the size of the next closest option, significantly expanding access to box-free, label-free returns with immediate refunds. This growth allows us to deliver unmatched convenience to online shoppers across the country.”

Security and speed across every return

Return Bar® locations deliver a consistent, reliable experience for both shoppers and retailers, combining fraud prevention with an optimized end-to-end logistics process.

Millions of shoppers bring their items to Return Bar® locations without packaging or printing a label. At drop off, store associates scan the item barcode to verify the return and issue an immediate refund. In the background, AI-powered Return Vision™ applies behavioral risk scoring to help flag and audit potentially risky returns early, safeguarding against return fraud.

Utilizing the full power of UPS’s integrated, end-to-end network — including RFID technology at The UPS Store® — returns now move from shopper drop-off back to retailers in as little as 3.6 days, with an average return transit time of seven days across all customers.

Now with 10,000 locations nationwide, Happy Returns’ Return Bar® network is the most comprehensive return network, delivering the convenience, fraud prevention and speed needed to manage returns at scale.

About UPS

UPS (NYSE: UPS) is one of the world’s largest companies, with 2025 revenue of $88.7 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 460,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. More information can be found at www.ups.com, about.ups.com and investors.ups.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421965642/en/

UPS Media Relations

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Other Transport Other Consumer Trucking Fashion Women Retail Transport Men Baby/Maternity Catalog Family Supply Chain Management Online Retail Consumer Logistics/Supply Chain Management Department Stores Other Retail Specialty

MEDIA:

Logo

April 21, 2026 12:03 pm

Comcast’s Xfinity and Adobe Co-innovate on Deep Brand Intelligence for Marketing Campaigns

Comcast’s Xfinity and Adobe Co-innovate on Deep Brand Intelligence for Marketing Campaigns

LAS VEGAS–(BUSINESS WIRE)–
Today at Adobe Summit — the flagship customer experience conference — Adobe (Nasdaq: ADBE) announced a new partnership with Xfinity, Comcast’s consumer brand delivering WiFi, mobile, entertainment, and home services to millions of customers across the U.S. The partnership will help accelerate on‑brand creative campaign production to help scale customized marketing messaging with improved efficiency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421794274/en/

As demand for timely, relevant content across channels continues to grow, this collaboration will enable Xfinity to design and build technology solutions that will scale creative production while strengthening a cohesive and consistent brand identity. Today, Xfinity’s marketing engine supports millions of customers with content built for relevance, reach, and consistency. Each campaign includes thousands of assets across platforms and cultural moments, often featuring beloved Comcast NBCUniversal franchises and characters all unified through carefully aligned brand standards.

To address this, Xfinity is testing Adobe Brand Intelligence across its end-to-end creative workflow. Layering this advanced AI across the content supply chain will embed brand governance directly into content creation and review. It moves teams beyond static brand guidelines, into a continuously-learning system that ingests qualitative and nuanced inputs such as review cycle feedback, annotations, rejections, and approvals.

“This partnership with Adobe allows us to embed brand intelligence into every step of our marketing workflows so our teams can spend less time managing work and more time crafting the standout storytelling that defines the Xfinity brand,” said Jon Gieselman, Chief Growth Officer, Connectivity & Platforms, Xfinity. “We’re quickly evolving how we work and are increasingly using agentic tools to remove friction from our processes, enabling our people to move faster, focus on creativity, and bring more authenticity and emotion into the stories we tell as part of the Xfinity ‘Imagine That’ brand platform.”

“Traditionally, brand governance has depended on static guidelines, point-in-time approvals, and manual reviews that struggle to keep pace as brands scale content across channels,” said Varun Parmar, Senior Vice President & General Manager, Adobe GenStudio and Firefly Enterprise at Adobe. “Adobe Brand Intelligence fundamentally changes this by embedding brand identity into production workflows so that teams can rapidly adapt content at scale while maintaining brand consistency and the trust audiences expect.”

Brand integrity at scale

With Adobe Brand Intelligence, Xfinity can reduce production bottlenecks caused by channel variants and inconsistent execution of brand standards that slow down internal reviews—factors that can extend campaign timelines by weeks. By weaving brand standards directly into production workflows, content variants can be assembled and validated at the same time, enabling teams to launch campaigns in days instead of weeks. Across multiple major campaigns during a six-month period in 2025, Xfinity teams identified thousands of brand validation issues such as tone, visual identity, layout, or compliance, resulting in rework that stretched campaign timelines.

These patterns highlighted the need for a solution that can identify issues earlier during creative production to accelerate go-to-market.

True personalization at scale

Targeted customer membership campaigns are some of the most complex Xfinity produces, requiring hundreds of custom creative variants across audiences, channels, and offers – each requiring strict brand adherence. To remove this complexity, Xfinity teams are looking to leverage Brand Intelligence in workflows for a new Xfinity membership campaign to streamline how assets are built and reviewed. Teams are piloting the new technology to assemble and validate hundreds of personalized display and email assets from a small set of base creatives, allowing brand compliance issues to be addressed as work progresses rather than cause bottlenecks later. This simplifies one of Xfinity’s most time-consuming processes and is critical for teams that previously could only deliver roughly 10% of the personalized content they wished to create for different audiences and moments.

Adobe Brand Intelligence has the potential to provide the foundation for Xfinity’s creative content supply chain, working alongside Adobe GenStudio for Performance Marketing, which Xfinity is also experimenting with to optimize campaign activation and performance measurement across channels. Together these solutions will fuel Xfinity’s end-to-end creative content workflow, integrated with Adobe Firefly Creative Production for Enterprise, where tasks such as resizing or background swapping will be automated and validated for brand compliance as assets are created. Xfinity also leverages Adobe Workfront, a work management application where Adobe Brand Intelligence helps shorten review cycles. Together, these solutions will help Xfinity unlock personalization at scale while driving engagement in an attention-based economy.

About Adobe

Adobe’s mission is to empower everyone to create by building innovative platforms and tools that unleash creativity, productivity and personalized customer experiences. For more visit www.adobe.com.

© 2026 Adobe. All rights reserved. Adobe and the Adobe logo are either registered trademarks or trademarks of Adobe in the United States and/or other countries. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421794274/en/

Patrick Heffernan

Adobe

[email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Carriers and Services Software Networks Internet Technology Artificial Intelligence Digital Marketing Marketing Advertising Audio/Video Content Marketing Communications Telecommunications

MEDIA:

Photo

Logo

April 21, 2026 12:03 pm

DICK’S Sporting Goods Partners with Adobe to Transform the Athlete Experience with AI

DICK’S Sporting Goods Partners with Adobe to Transform the Athlete Experience with AI

LAS VEGAS–(BUSINESS WIRE)–
Today, at Adobe Summit—the flagship customer experience conference—Adobe (Nasdaq:ADBE)—the global technology leader that unleashes creativity, productivity and customer experiences through innovative tools and platforms—announced a major partnership with DICK’S Sporting Goods (NYSE:DKS) to reshape how DICK’S connects with its customers (whom the company refers to as athletes) at every stage of the athlete journey.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421672910/en/

Athletes today—no matter if they are active sports participants, weekend warriors, or fans—expect a high level of personalization and guidance that is tailored to their specific goals. DICK’S is partnering with Adobe to respond to this need with AI capabilities that equip every athlete with a digital coach. DICK’S will also leverage a suite of Adobe enterprise solutions, along with its own product, service and sport knowledge, to ensure athlete experiences are tailored and consistent.

“Every athlete’s journey is unique, and it is our job to ensure that every interaction with our brand is focused on helping our athletes achieve their dreams,” said Emily Silver, Chief Marketing, e-Commerce and Athlete Experience Officer, DICK’S. “Our partnership with our technology team and Adobe will help us meet the promise of personalization at scale through AI, with a data and content foundation that enables our teams to deliver the power of our opinion and expert knowledge and create unique experiences for every athlete.”

“With Adobe, we are further differentiating the experiences for our athletes across all parts of their journey,” said Vlad Rak, Chief Technology Officer, DICK’S. “From stores to online, from shopping to performance services, AI capabilities – powered by our deep knowledge of athletes and sport – are becoming the pillar of our strategy.”

“DICK’S Sporting Goods is writing the playbook for the modern athlete experience, moving to immersive and interactive engagements that are highly personalized, in their stores and online,” said Rachel Thornton, Chief Marketing Officer, Adobe Enterprise. “Our partnership speaks to the value that AI can bring when CMOs and CTOs collaborate, building on top of an integrated customer data platform, that makes it easier for marketing teams to understand preferences and deliver experiences that are intuitive, relevant and deepen brand loyalty.”

DICK’S is partnering with Adobe to enable:

Agent-powered conversational experiences: Consumers are embracing LLM interfaces to discover and engage their favorite brands. Data from Adobe showed that during the 2025 holiday season, AI traffic to retail sites (users clicking a link) jumped 693% year-over-year, as shoppers engaged with AI to locate specific products or find deals. DICK’S will leverage Adobe Brand Concierge to address this shift in consumer preferences, delivering immersive conversational experiences on its mobile app. AI agents (acting as digital coaches) will guide DICK’S athletes in their journey from personalized product recommendations informed by specific athlete needs to tailored training tips. Anchored in timely and relevant data, teams can also ensure that every agent interaction is customized and reacts to athletes’ changing preferences.
Personalization across every touchpoint: DICK’S is working with Adobe to ensure that a high bar for personalization exists across any athlete touchpoint. With Adobe Experience Platform, DICK’S is bringing together data signals across athlete interactions to more deeply understand athletes’ needs and preferences. Teams can then build relevant audiences through Adobe Real-Time Customer Data Platform and orchestrate cross-channel experiences via Adobe Journey Optimizer. This enables DICK’S to deliver the right content at just the right moment to create impact and boost engagement.
On-brand content production: Personalization at scale requires a high volume of content, with variations that must be tailored to either individuals or distinct customer cohorts. DICK’S is partnering with Adobe to streamline its content supply chain via Adobe GenStudio, leveraging a suite of best-in-class solutions that make it easier to get from idea to execution and delivery and respond to everchanging consumer trends and needs. This content engine includes Adobe Workfront to support effective cross-team collaboration, Adobe Experience Manager to drive how assets are managed and activated, and Adobe Firefly Services and Custom Models for teams to generate on-brand content and deliver variations for different marketing channels.

About Adobe

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421672910/en/

Kevin Fu

Adobe

[email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Technology Other Retail Marketing Communications Specialty Software Digital Marketing Retail Artificial Intelligence Online Retail

MEDIA:

Photo

Logo

April 21, 2026 11:54 am

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

New evidence for established standard-of-care therapies, with updates for LORBRENA^® in ALK-positive metastatic non‑small cell lung cancer and a BRAFTOVI^® regimen in a type of BRAF-mutant colorectal cancer
Extending potential impact of innovative therapies in earlier lines of treatment, including TALZENNA^® plus XTANDI^® in metastatic castration-sensitive prostate cancer and TUKYSA^® as first-line maintenance for HER2-positive breast cancer
New and updated data from next-generation pipeline of novel mechanisms and differentiated combinations across solid tumors, including sigvotatug vedotin, PF-08634404 and atirmociclib

NEW YORK–(BUSINESS WIRE)–
Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – June 2, 2026, in Chicago. Data from more than 40 company-sponsored, investigator-sponsored and collaborative research abstracts, including three late-breaking sessions and eight oral and rapid oral presentations, will be shared. These data highlight Pfizer’s leadership in establishing potential new standards of care across multiple cancer types and its next-generation pipeline of novel targets and combination strategies designed to extend impact into broader patient populations and earlier lines of therapy.

“For people living with cancer and their families, every moment matters. We are moving with urgency to drive advances that have the potential to change standards of care – and striving to bring new, innovative options to patients in earlier lines of therapy,” said Jeff Legos, Chief Oncology Officer, Pfizer. “Our progress is evident in the data presented at ASCO this year, which span our portfolio of established therapies, as well as next-generation, early-stage clinical research from one of the industry’s largest oncology R&D programs. Together, these results reinforce our ability to advance breakthroughs that may redefine clinical practice and change the lives of people with cancer.”

Key highlights of Pfizer’s presence at ASCO include:

Sharing new evidence for standard-of-care therapies in certain types of biomarker-driven colorectal and lung cancers

Seven-year update from the pivotal Phase 3 CROWN study further supports LORBRENA^® (lorlatinib) as a guideline-recommended first-line treatment for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
Late-breaking presentation of progression-free survival (PFS) and overall survival (OS) data from Cohort 3 of the BREAKWATER* trial evaluating BRAFTOVI^® (encorafenib) in combination with cetuximab and FOLFIRI (fluorouracil, leucovorin and irinotecan) as a first-line regimen for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). These pivotal data further establish the benefit of this BRAFTOVI regimen following the U.S. Food and Drug Administration (FDA) full approval and the topline results announcement for objective response rate (ORR) from this Cohort earlier this year.

Showcasing data on potential benefit of treatments in earlier lines of therapy for prostate and breast cancers

Late-breaking presentation from the Phase 3 TALAPRO-3 study will highlight clinically meaningful radiographic progression-free survival (rPFS) benefit for TALZENNA^® (talazoparib) plus XTANDI^®** (enzalutamide) in metastatic castration‑sensitive prostate cancer (mCSPC) patients with homologous recombination repair gene alterations, with effects consistent across subgroups and a strong OS trend. These data follow the announcement of topline results in March 2026 and support the potential of TALZENNA plus XTANDI to deliver benefit earlier in the disease course.
Additional efficacy and safety outcomes by stratified subgroups from the Phase 3 HER2CLIMB-05 study investigating TUKYSA^® (tucatinib) in combination with trastuzumab and pertuzumab as first-line maintenance therapy for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). These results support TUKYSA’s potential use as part of a chemotherapy-free, first-line maintenance strategy for HER2+ MBC.

Advancing next-generation pipeline of novel mechanisms and differentiated combinations across solid tumors

Updated Phase 2 data for PF‑08634404 (PF’4404), a novel bispecific antibody targeting PD-1 and VEGF, as monotherapy in first-line PD-L1-expressing NSCLC. PF’4404 is being developed as a potential backbone therapy across tumor types, including an ongoing Symbiotic-Lung-01 Phase 3 study in combination with chemotherapy in first-line NSCLC regardless of PD-L1 expression and an ongoing Symbiotic-GI-03 Phase 3 study in first-line mCRC.
Updated results from a Phase 1 study of sigvotatug vedotin (SV), a novel integrin β6 (IB6)–directed ADC, in combination with pembrolizumab in NSCLC. These data support the ongoing SigVie-003 Phase 3 study of SV in combination with pembrolizumab in first-line NSCLC. An additional ongoing Phase 3 study, SigVie-002, is evaluating SV monotherapy in patients previously treated for advanced NSCLC.
The first results from a Phase 2 study of neoadjuvant atirmociclib, a highly selective CDK4 inhibitor, in combination with letrozole versus letrozole alone in people with hormone receptor-positive (HR+), HER2- breast cancer. Atirmociclib is being developed as a potential first-in-class, next-generation cell cycle inhibitor backbone for HR+, HER2- breast cancer in the early adjuvant and first-line metastatic setting.
Findings from a Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544 (polfurmetinib), plus a next-generation BRAF inhibitor, PF-07799933 (claturafenib), in advanced BRAF-mutant melanoma.

Information on significant Pfizer and partner-sponsored abstracts, including date and time of presentation, follows in the chart below. A complete list of Pfizer and partner-sponsored abstracts and presentations is available here.

LUNG CANCER

Oral Presentation (Abstract 8502)

May 29, 2026 1:00 PM-4:00 PM CDT

Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study

Mok et al

Rapid Oral Presentation (Abstract 8514)

May 30, 2026 1:15 PM-2:45 PM CDT

Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC)

Wu et al

Poster Presentation (Abstract 8522)

May 31, 2026 9:00 AM-12:00 PM CDT

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody-drug conjugate (ADC), plus pembrolizumab: updated results from phase 1 study (SGNB6A-001)

Jaime et al

Poster Presentation (Abstract 8609)

May 31, 2026 9:00 AM-12:00 PM CDT

Reduction in circulating tumor DNA (ctDNA) significantly correlates with radiographic response and tumor PD-L1 expression in a phase 1 study of PDL1V (PF-08046054) in patients with non-small cell lung cancer (NSCLC)

Saleh et al

COLORECTAL CANCER

Oral Presentation (Abstract LBA3503)

May 31, 2026 8:00 AM-11:00 AM CDT

BREAKWATER: Progression-free survival analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC) [LBA]

Kopetz et al

BREAST CANCER

Oral Presentation (Abstract 1005)

June 2, 2026 9:45 AM-12:45 PM CDT

Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer (MBC) by stratified randomized subgroups

Hamilton et al

Rapid Oral Presentation (Abstract LBA1018)

May 31, 2026 11:30 AM-1:00 PM CDT

Palbociclib plus Tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial: Final Overall Survival (OS) analysis [LBA]

Lu et al

Poster Presentation (Abstract 518)

June 1, 2026 1:30 PM-4:30 PM CDT

Neoadjuvant atirmociclib plus letrozole versus letrozole alone in women with HR+/HER2− breast cancer: results from FOURLIGHT-2, a randomized phase 2 window of opportunity study

Goel et al

Poster Presentation (Abstract 1042)

June 1, 2026 1:30 PM-4:30 PM CDT

Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): an in-depth safety analysis of HER2CLIMB-05

Dieras et al

Poster Presentation (Abstract 1068)

June 1, 2026 1:30 PM-4:30 PM CDT

Long-term safety and adverse event (AE) management in patients with ER+/HER2− metastatic breast cancer (mBC) receiving prifestrastat, a first-in-class KAT6 inhibitor, in combination with fulvestrant

Layman et al

BLADDER/GENITOURINARY CANCERS

Oral Presentation (Abstract LBA5007)

May 30, 2026 3:00 PM-6:00 PM CDT

TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations [LBA]

Agarwal et al

Oral Presentation (Abstract 4507)

May 29, 2026 2:45 PM-5:45 PM CDT

Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study

Powles et al

Oral Presentation (Abstract 4510)

May 30, 2026 8:00 AM-9:30 AM CDT

Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: phase 3 KEYNOTE-905 study [MSD led]

O’Donnell et al

Oral Presentation (Abstract 5006)

May 30, 2026 3:00 PM-6:00 PM CDT

Final results from ZZFIRST: a randomized phase 2 trial of enzalutamide (EZ) and talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)

Mateo et al

Poster Presentation (Abstract 4613)

May 31, 2026 9:00 AM-12:00 PM CDT

Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905 [MSD led]

Adra et al

Poster Presentation (Abstract 5043)

May 31, 2026 9:00 AM-12:00 PM CDT

Impact of baseline demographics on therapy management in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib (TALA) + enzalutamide (ENZA) in the TALAPRO-2 study: extended follow-up

De Giorgi et al

MELANOMA

Rapid Oral Presentation (Abstract 9512)

May 30, 2026 4:30 PM-6:00 PM CDT

Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF-mutant melanoma

Chen et al

MULTIPLE MYELOMA

Oral Presentation (Abstract 7500)

May 29, 2026 2:45 PM-5:45 PM CDT

Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study

Touzeau et al

OTHER GYNECOLOGICAL CANCERS

Poster Presentation (Abstract 5627)

June 1, 2026 9:00 AM-12:00 PM CDT

A phase 2 study evaluating SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, + chemotherapy (chemo) in patients (pts) with first-line (1L) advanced/recurrent endometrial cancer (EC)

Zhou et al

Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (APLS) for company-sponsored research being presented at ASCO, which are written in non-technical language. Those interested in learning more can visit www.Pfizer.com/apls to access the summaries.

*The BREAKWATER trial was conducted with support from ONO Pharmaceutical, Merck KGaA, Darmstadt, Germany and Eli Lilly and Company. Pierre Fabre Laboratories also has exclusive rights to commercialize the product in all other countries, including Europe and Asia (excluding Japan and South Korea).

**XTANDI^® is jointly developed and commercialized by Pfizer and Astellas in the United States.

Prescribing Information for Pfizer Medicines

Please see full Prescribing Information for LORBRENA^®(lorlatinib).

Please see full Prescribing Information for BRAFTOVI^®(encorafenib).

Please see full Prescribing Information for TALZENNA^®(talazoparib).

Please see full Prescribing Information for XTANDI^® (enzalutamide).

Please see full Prescribing Information for TUKYSA^® (tucatinib).

About Pfizer Oncology

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, and lung cancers. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on X at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice

The information contained in this release is as of April 21, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer Oncology and Pfizer’s oncology portfolio of marketed and investigational therapies, including their potential benefits; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications or combinations, including expected clinical trial protocols, the potential and timing for the initiation and progress of clinical trials and data read-outs from trials; the timing and potential for the submission of applications for and receipt of regulatory approvals; the timing and potential for product launches and commercialization; expected breakthrough, best- or first-in-class or blockbuster status or expected market entry of our medicines; potential patients reached; the regulatory landscape; the competitive landscape; and other statements about our business, operations and financial results that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s oncology portfolio; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s products or product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260420004885/en/

Media Contact:

+1 (212) 733-1226

[email protected]

Investor Contact:

+1 (212) 733-4848

[email protected]

KEYWORDS: Illinois New York United States North America

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo

April 21, 2026 11:26 am

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) will be presented in a Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago.

Revolution Medicines recently reported an unprecedented overall survival (OS) benefit with daraxonrasib from the RASolute 302 clinical trial. These topline results showed that daraxonrasib taken once daily orally met all primary and key secondary endpoints, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and OS compared with standard of care intravenous cytotoxic chemotherapy. The presentation will describe these findings, as well as additional analyses of efficacy and safety.

Presentation Details

Presenting Author: Brian M. Wolpin, M.D., M.P.H., Dana-Farber Cancer Institute
Title: Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study
Abstract: LBA5
Session Name: Plenary Session
Session Date: May 31, 2026
Presentation Time: 3:21-3:33 PM CDT
Location: McCormick Place, Hall B1

Additional Accepted Abstracts

The following additional Revolution Medicines–sponsored abstracts have been accepted for online publication:

Systemic anticancer therapy in patients with de novo metastatic pancreatic adenocarcinoma: a real-world analysis (Abstract #e16383)
Patient characteristics, treatment patterns, and survival in a metastatic pancreatic adenocarcinoma U.S. patient population (Abstract #e16379)
Safety and efficacy of daraxonrasib monotherapy as later-line (3L+) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) (Abstract #e15104)

About the RASolute 302 Clinical Trial

RASolute 302 (NCT06625320) is a global, randomized Phase 3 registrational clinical trial designed to evaluate the efficacy and safety of daraxonrasib as a monotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). In the trial, patients were randomized to receive either an oral dose of 300 mg daraxonrasib once daily or investigator’s choice of standard of care cytotoxic chemotherapy. The trial enrolled patients with metastatic PDAC harboring a wide range of RAS variants, including those with RAS G12 mutations (such as G12D, G12V, and G12R), as well as patients without an identified tumor RAS mutation (wild type).

The primary endpoints of RASolute 302 are progression-free survival (PFS), as assessed by a Blinded Independent Central Review, and overall survival (OS) in patients with tumors harboring RAS G12 mutations. Secondary endpoints include PFS and OS in all enrolled patients (the intent-to-treat population) encompassing patients with and without identified tumor RAS mutations, as well as objective response rate, duration of response, and patient-reported quality of life.

About Daraxonrasib

Daraxonrasib is an investigational, oral RAS(ON) multi-selective, non-covalent inhibitor that is not approved by any regulatory authority, including in the United States or Europe. The U.S. Food and Drug Administration (FDA) granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation for the treatment of patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) harboring G12 mutations. In addition, daraxonrasib was selected for the FDA Commissioner’s National Priority Voucher pilot program, which is intended to accelerate the development and review of therapies aligned with U.S. national health priorities.

Daraxonrasib is designed to target cancers driven by a broad range of common RAS mutations, including PDAC, non-small cell lung cancer (NSCLC), and colorectal cancer. In addition to the RASolute 302 trial, daraxonrasib is being evaluated in three other global Phase 3 registrational trials, including in patients with PDAC and metastatic RAS mutant NSCLC.

Daraxonrasib works by suppressing RAS signaling through inhibition of the interaction between both wild-type and mutant RAS(ON) proteins and their downstream effectors.

About Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma

Pancreatic cancer is one of the most lethal malignancies, characterized by its typically late-stage diagnosis, resistance to standard chemotherapy, and high mortality rate. In the U.S., recent estimates indicate that annually approximately 60,000 people will be diagnosed with pancreatic cancer, and about 50,000 people will die from this aggressive disease.¹

Due to the lack of early symptoms and detection methods, approximately 80% of patients are diagnosed with PDAC at an advanced or metastatic stage. It is the most commonly RAS-addicted of all major cancers, and more than 90% of patients have tumors that harbor RAS mutations.² Metastatic PDAC remains one of the most common causes of cancer-related deaths in the U.S., with a five-year survival rate of approximately 3%.^3,4

About Revolution Medicines, Inc.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the company’s development strategy and its ability to build or advance its portfolio and R&D pipeline; and progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s candidates being studied.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “potential,” “project,” “up to,” “will” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 25, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contact:

[email protected]

[email protected]

References
¹ Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820
²Lee JK, Sivakumar S, Schrock AB, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;6(1);91. doi:10.1038/s41698-022-00334-z.
³Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186(8):1729-1754. doi:10.1016/j.cell.2023.02.014
⁴American Cancer Society. Survival Rates for Pancreatic Cancer. Available at: https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html. Accessed April 2026.

April 21, 2026 11:09 am

UBS Hires Financial Advisor Brad Gillin in New York City

UBS Hires Financial Advisor Brad Gillin in New York City

NEW YORK–(BUSINESS WIRE)–
UBS today announced that Brad Gillin will be joining the firm as a Financial Advisor. Following the conclusion of his notice period, Brad will join the UBS Manhattan Market, led by Market Executive Kellie Brady, and will be based in the firm’s 1285 Avenue of the Americas Private Wealth Management office. He will report to Senior Market Director Tom Conigatti.

“We are thrilled that Brad will be joining UBS,” said Kellie Brady, Manhattan Market Executive at UBS. “His experience advising highly sophisticated clients makes him a strong fit for our Manhattan market. Brad’s collaborative approach and understanding of complex wealth needs align well with UBS’s global capabilities and long‑term commitment to our clients.”

“Brad brings a thoughtful, client‑first approach and a strong track record advising families and professionals with complex needs,” said Tom Conigatti, UBS Market Director. “We look forward to welcoming him to UBS and supporting him as he delivers tailored strategies backed by the depth of UBS’s resources.”

Brad will join UBS from Deutsche Bank Wealth Management, where he most recently served as a Director in the firm’s New York City office. A next-generation advisor, he began his career at Deutsche Bank in 2006 as a Client Associate for one of the firm’s top advisors before transitioning into a private banking role and building his own practice over the past seven years.

At UBS, Brad will advise ultra-high net worth families and financial professionals, including private equity partners, on a range of services including asset allocation, investment portfolio construction, customized lending and liquidity strategies, and wealth transfer planning.

Brad will join the Baum Investment Group, a leading private wealth management team at UBS that manages portfolios for ultra-high net worth families, business owners, foundations and trusts. The team is led by Jamie Baum, Managing Director and Private Wealth Advisor, who joined UBS in 2010 from Deutsche Bank and has over three decades of industry experience.

Brad lives in Darien, Connecticut, and holds a bachelor’s degree from Lehigh University.

Notes to Editors

About UBS

UBS is a leading and truly global wealth manager and the leading universal bank in Switzerland. It also provides diversified asset management solutions and focused investment banking capabilities. UBS manages 7 trillion dollars of invested assets as per the fourth quarter 2025. UBS helps clients achieve their financial goals through personalized advice, solutions and products. Headquartered in Zurich, Switzerland, the firm is operating in more than 50 markets around the globe. UBS Group shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).

https://www.ubs.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421193839/en/

Media Contact:

Christina Aquilina

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Finance Consulting Banking Professional Services Asset Management

MEDIA:

Logo

April 21, 2026 11:05 am

CORRECTING and REPLACING: CPI Announces Partnership with Street Charity® to Launch a Groundbreaking New Payments Solution to Combat Hunger

CORRECTING and REPLACING: CPI Announces Partnership with Street Charity® to Launch a Groundbreaking New Payments Solution to Combat Hunger

CPI’s solutions help Street Charity® fight hunger with an innovative payment tool at a time when consumers carry less cash and needs surge

Nearly 50 million Americans are food insecure, including almost one in five children
Ongoing shift toward contactless payments means fewer donors carry cash
U.S. consumers make nearly 50 payments a month; only seven of them or 14% are made in cash, while payment cards account for 65% of payments
Paper prepaid payment cards are redeemable for food at chain restaurants, giving donors peace of mind and recipients the dignity to choose their own food

DENVER–(BUSINESS WIRE)–
The second paragraph of release should read: This announcement comes during the ICMA EXPO 2026 hosted by the International Card Manufacturers Association in Orlando, Fla.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421134871/en/

The updated release reads:

CPI ANNOUNCES PARTNERSHIP WITH STREET CHARITY® TO LAUNCH A GROUNDBREAKING NEW PAYMENTS SOLUTION TO COMBAT HUNGER

CPI’s solutions help Street Charity® fight hunger with an innovative payment tool at a time when consumers carry less cash and needs surge

Nearly 50 million Americans are food insecure, including almost one in five children
Ongoing shift toward contactless payments means fewer donors carry cash
U.S. consumers make nearly 50 payments a month; only seven of them or 14% are made in cash, while payment cards account for 65% of payments
Paper prepaid payment cards are redeemable for food at chain restaurants, giving donors peace of mind and recipients the dignity to choose their own food

CPI Card Group (Nasdaq: PMTS), a payments technology company providing a comprehensive range of physical and digital payment solutions, is celebrating Earth Day by announcing its partnership with Street Charity®, a nonprofit focused on combating hunger by leveraging the power of fintech and the reach of quick-serve chain restaurants. To support the national rollout, CPI has donated 25,000 paper cards, along with a monetary contribution.

This announcement comes during the ICMA EXPO 2026 hosted by the International Card Manufacturers Association in Orlando, Fla.

Atlanta-based Street Charity® uniquely fights the issue of hunger and food insecurity by providing $5 Street Charity® Discover® Network Prepaid Cards that can be used only at fast-food and quick-serve restaurants nationwide. As the nonprofit’s impact expands nationwide, CPI is supporting them with a shift from traditional plastic cards to a single-use paper prepaid card and multi-card carrier system to support distribution at scale.

Donors to Street Charity® can receive cards in bulk or subscribe to a monthly fulfillment model. A hybrid distribution ensures that cards are produced accurately, personalized reliably, and delivered on time — a critical capability for Street Charity® to support crisis centers, shelters, and nonprofit partners that help individuals experiencing food insecurity. Donors who don’t typically carry cash also appreciate the ability to give meals rather than money.

“We created Street Charity® in response to seeing more and more people asking for help. With Street Charity® cards, hungry people can eat what they want and where they want — with a big side dish of dignity,” said John Patton, who co-founded the organization with his wife Antuanette Patton. “Working with CPI has helped us streamline our card personalization and fulfillment process across our nonprofit and agency partners, corporate donors, and individual subscribers. The strong partnership we are announcing today means so much to us and to the thousands of people who have been able to give or enjoy the gift of a hot meal.”

“It is fitting to celebrate this powerful Street Charity® program on the eve of Earth Day,” said Chris Green, VP, Digital Sales for CPI. “Not only are we able to serve an urgent need to pay for meals in an increasingly cashless society, but we’re also creating single-use paper prepaid cards in a more sustainable way.”

Since 2022, CPI has produced nearly 100 million eco-focused paper payment cards, which offer a durable design for single-use while avoiding plastic.

Street Charity® distributes the majority of its cards in bulk to partner organizations, including the Latin American Association, Atlanta Dream Center, Agape Family Center, The Salvation Army, and various elementary schools supporting homeless students.

About CPI Card Group Inc.

CPI Card Group (Nasdaq: PMTS) is a payments technology company that is integral to the payments ecosystem. CPI’s connections, people, and solutions enable payments for a broad and expanding customer base including thousands of U.S. financial institutions, processors, fintechs, prepaid program managers and more, and these customers count on us to deliver what’s next. We continue to transform alongside the market, and for decades have invested in building deep connections and flexible solutions for our customers. Our proprietary platform and expertise uniquely position CPI to deliver today, tomorrow, and into the future as the market expands and payment methods evolve. Learn more at www.cpicardgroup.com.

About Street Charity®

Founded by John and Antuanette Patton, Street Charity’s mission is to equip people and organizations with innovative tools to help address hunger in their own community. Street Charity® is the only organization to leverage the power of fintech and the infrastructure of quick-serve restaurants to address food insecurity in every corner of the country. Street Charity® Discover® Network Prepaid Cards deliver dignity by allowing all individuals to choose what, where, and when they want to eat. To learn more, visit https://streetcharity.org.

The Street Charity® Discover® Network Prepaid Card is issued by the Central Bank of Kansas City, Member FDIC, pursuant to a license from Discover Network. Discover Network and the Discover Acceptance Mark are service marks used by the Central Bank of Kansas City under license from DFS Services LLC. The card can be used only at quick-serve restaurants in the United States, where Discover is accepted. Certain terms and conditions are associated with the approval, maintenance, and use of the Card. Consult the Cardholder Agreement. Card funds are not FDIC insured. No Cash or ATM Access. For transaction and balance information and customer service, call 1-844-404-0244.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421134871/en/

MEDIA CONTACTS:

CPI

Solomon Joseph

(905) 510-1400

[email protected]

Street Charity®

Amanda Brown Olmstead

Jonathan Olens

A. Brown Olmstead Associates

404-659-0919

[email protected]

[email protected]

KEYWORDS: Colorado Georgia Florida United States North America

INDUSTRY KEYWORDS: Technology Payments Fintech Professional Services Software Restaurant/Bar Food/Beverage Retail Data Management

MEDIA:

Photo

Logo

April 21, 2026 11:04 am

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—GSAT, GRTX, WBS, and FORA

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) —

Class Action Attorney
Juan Monteverde
with

Monteverde & Associates PC
(the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

Globalstar, Inc. (NASDAQ:

GSAT

) related to its sale to Amazon.com, Inc. Under the terms of the proposed transaction, Globalstar shareholders will receive $90.00 per share in cash or 0.3210 shares of Amazon common stock with a value capped at $90.00 per share.

Click here for more information

https://monteverdelaw.com/case/globalstar-inc-2/

. It is free and there is no cost or obligation to you.

Galera Therapeutics, Inc. (OTCMKTS:

GRTX

) related to its merger with Obsidian Therapeutics, Inc. Upon completion of the proposed transaction, Galera shareholders will own approximately 1.8% of the combined company.

Click here for more information

https://monteverdelaw.com/case/galera-therapeutics-inc/

. It is free and there is no cost or obligation to you.

Webster Financial Corporation (NYSE:

WBS

) related to its sale to Banco Santander, S.A. Under the terms of the proposed transaction, Webster shareholders are expected to receive $48.75 in cash and 2.0548 Santander American Depository Shares for each Webster common share.

ACT NOW. The Shareholder Vote is scheduled for May 26, 2026.

Click here for more information

https://monteverdelaw.com/case/talkspace-inc/

. It is free and there is no cost or obligation to you.

Forian Inc. (NASDAQ:

FORA

) related to its sale to a consortium led by Max Wygod, Chairman and Chief Executive Officer, together with certain other senior executives and existing shareholders of the company. Under the terms of the proposed transaction, Forian shareholders are expected to receive $2.17 per share in cash.

Click here for more info

https://monteverdelaw.com/case/forian-inc/

.
It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

Do you file class actions and go to Court?
When was the last time you recovered money for shareholders?
What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.

No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.